Lucien Goffart
Directeur Général chez Robocath SAS
Profil
Lucien Goffart is currently the Chief Executive Officer at Robocath SAS since 2019.
Prior to this, he held the position of Independent Director at Opsens, Inc. He also served as the General Manager-Europe at Mitralign, Inc. and as the Vice President-Sales & Marketing at Stentys SA.
Postes actifs de Lucien Goffart
| Sociétés | Poste | Début |
|---|---|---|
Robocath SAS
 Robocath SAS Miscellaneous Commercial ServicesCommercial Services Robocath SAS develops robotics medical devices for cardiac pathologies. It allows doctors to perform coronary angioplasties by controlling the catheters whilst seating behind a control station that is protected from X-rays. The company was founded by Philippe Bencteux in 2009 and is headquartered in Rouen, France. | Directeur Général | 03/09/2019 |
Anciens postes connus de Lucien Goffart
| Sociétés | Poste | Fin |
|---|---|---|
| OPSENS INC. | Directeur/Membre du Conseil | 16/09/2015 |
Mitralign, Inc.
 Mitralign, Inc. Medical SpecialtiesHealth Technology Mitralign, Inc. operates as a valve repair company that engages in transcatheter annuloplasty system designed to treat both functional tricuspid regurgitation and mitral regurgitation. The Mitralign Percutaneous Annuloplasty System, MPAS, is intended for the treatment of symptomatic functional mitral regurgitation for annular reduction through tissue plication. The company was founded by Paul A. Spence and Richard P. Geoffrion in 2003 and is headquartered in Tewksbury, MA. | Corporate Officer/Principal | - |
| STENTYS | Sales & Marketing | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Mitralign, Inc.
Mitralign, Inc. Medical SpecialtiesHealth Technology Mitralign, Inc. operates as a valve repair company that engages in transcatheter annuloplasty system designed to treat both functional tricuspid regurgitation and mitral regurgitation. The Mitralign Percutaneous Annuloplasty System, MPAS, is intended for the treatment of symptomatic functional mitral regurgitation for annular reduction through tissue plication. The company was founded by Paul A. Spence and Richard P. Geoffrion in 2003 and is headquartered in Tewksbury, MA. | Health Technology |
Opsens, Inc.
 Opsens, Inc. Medical SpecialtiesHealth Technology Opsens, Inc. engages in the development, manufacture, supply, and installation of fiber optic systems for measuring pressure and temperature. It operates through the Medical and Industrial business segments. The Medical segment focuses on the physiological measurement in interventional cardiology. The Industrial segment develops, manufactures, and installs fiber optic sensing solutions for critical applications such as the monitoring of oil wells and demanding industrial applications. The company was founded in 2003 and is headquartered in Quebec, Canada. | Health Technology |
Stentys SA
 Stentys SA Medical SpecialtiesHealth Technology Stentys SA engages in the design, development, and marketing of self-expanding stents used in treating cardiovascular diseases. It provides solutions for the treatment of acute myocardial infarction and other complex coronary diseases. Its products include Xposition S, Devoir, AmazoniaSir, stemiCath, Yangtzenano and YangtzeNC. The company was founded by Gonzague Issenmann and Jacques Seguin on July 6, 2006 and is headquartered in Neuilly-sur-Seine, France. | Health Technology |
Robocath SAS
Robocath SAS Miscellaneous Commercial ServicesCommercial Services Robocath SAS develops robotics medical devices for cardiac pathologies. It allows doctors to perform coronary angioplasties by controlling the catheters whilst seating behind a control station that is protected from X-rays. The company was founded by Philippe Bencteux in 2009 and is headquartered in Rouen, France. | Commercial Services |